Brokerages Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Price Target at $12.38

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) have been given an average recommendation of “Buy” by the five analysts that are presently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $12.38.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a research note on Tuesday, January 14th.

Corvus Pharmaceuticals Trading Up 2.4 %

Shares of NASDAQ CRVS opened at $4.31 on Tuesday. The firm has a market capitalization of $276.95 million, a PE ratio of -4.63 and a beta of 0.91. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00. The firm’s 50-day moving average is $4.74 and its 200-day moving average is $6.08.

Institutional Trading of Corvus Pharmaceuticals

A number of hedge funds have recently modified their holdings of CRVS. Virtus ETF Advisers LLC acquired a new stake in shares of Corvus Pharmaceuticals in the 4th quarter valued at approximately $47,000. Nwam LLC acquired a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter valued at approximately $53,000. PKS Advisory Services LLC acquired a new stake in Corvus Pharmaceuticals during the 4th quarter worth approximately $56,000. Alpine Global Management LLC acquired a new stake in Corvus Pharmaceuticals during the 4th quarter worth approximately $62,000. Finally, ExodusPoint Capital Management LP acquired a new stake in Corvus Pharmaceuticals during the 4th quarter worth approximately $72,000. 46.64% of the stock is currently owned by institutional investors and hedge funds.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.